InMode Ltd. demonstrates impressive net income growth from non-invasive surgical products, with new platforms Define and Envision expected to drive future business growth. The company's innovative technologies in plastic surgery, dermatology, gynecology, and ophthalmology, along with ongoing stock repurchases, make InMode a compelling buy. Strong financials show consistent income growth and sig...
YOKNEAM, Israel , Nov. 6, 2024 /PRNewswire/ -- InMode Ltd. (Nasdaq: INMD), a leading global provider of innovative medical technologies, today announced the participation at the following investor conferences in November and December: UBS Global Healthcare Conference Presenters: Yair Malca, Chief Financial Officer Format: In-person fireside chat moderated by Danielle Antalffy, Senior Equity Ana...
Elevated interest rates continue to hurt InMode's revenue, especially as lease package interest rates haven't fallen yet. Still, future rate cuts could release pent-up demand. InMode continues to buy back shares at a low price, which will boost per-share results. InMode's manufacturing is done in Israel, presenting a risk, but the company has been managing this well despite the war.
InMode's products are part of the medical aesthetics industry that is expected to grow at an 11% CAGR over the next five years. Despite a punishing macro environment of late that has seen its share price decline over 80% from its peak, InMode has remained profitable while continuing to innovate. The strong new and second-hand sales market for their platforms suggest their customers continue to ...
InMode Ltd. (NASDAQ:INMD ) Q3 2024 Earnings Conference Call October 30, 2024 8:30 AM ET Company Participants Miri Segal - CEO, MS-IR Moshe Mizrahy - Chief Executive Officer Michael Kreindel - Chief Technology Officer Yair Malca - Chief Financial Officer Eran Krieger - Medical Director and VP of Medical Affairs Rafael Lickerman - Vice President, Finance Conference Call Participants Matt Miksic -...
YOKNEAM, Israel, Oct. 30, 2024 /PRNewswire/ -- InMode Ltd. (Nasdaq: INMD) ("InMode"), a leading global provider of innovative medical technologies, today announced its consolidated financial results for the third quarter ended September 30, 2024.
Expects Q3 Revenue Between $130.0 Million -$130.1 Million (including $31.9 Million in Revenue from First Half of 2024 Pre-orders), Decreases Full Year 2024 Guidance to $410 Million-$420 Million Conference call to be held on Wednesday, October 30, 2024, at 8:30 a.m. Eastern Time YOKNEAM, Israel, Oct. 10, 2024 /PRNewswire/ -- InMode Ltd.
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.